Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WR | N.MMED.WS | N.MMED | N.MMED.WA

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

<< Previous

Bullboard Posts

Next >>

Post by MrVerbatim9800on Jan 12, 2021 3:40pm

208 Views

Post# 32278277

MindMed Expands Psychedelic Microdosing Division, Adds......

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body

NEW YORK, Jan. 12, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NEO:MMED)(DE: BGHM)(OTC:MMEDF), a leading psychedelic medicine biotech company today announced an innovative randomized placebo-controlled study evaluating the effects of daytime and evening administration of low doses of LSD on cognitive performance, sleep quality, mood, neuroplasticity markers, emotion regulation, quality of life, and immune system response.

The study will provide an additional research pathway for MindMed’s psychedelic Microdosing Division and will ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer .

For further details see:

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

Source: MicroSmallCap (Jan 12, 2021 10:18:05 EST)

News by QuoteMedia
www.quotemedia.com

<< Previous

Bullboard Posts

Next >>

Mid-year update: Charting GameSquare’s sharp business growth